257 related articles for article (PubMed ID: 35704032)
1. Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction.
Dulce RA; Kanashiro-Takeuchi RM; Takeuchi LM; Salerno AG; Wanschel ACBA; Kulandavelu S; Balkan W; Zuttion MSSR; Cai R; Schally AV; Hare JM
Cardiovasc Res; 2023 Feb; 118(18):3586-3601. PubMed ID: 35704032
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a growth hormone-releasing hormone agonist in a murine model of cardiometabolic heart failure with preserved ejection fraction.
Kanashiro-Takeuchi RM; Takeuchi LM; Dulce RA; Kazmierczak K; Balkan W; Cai R; Sha W; Schally AV; Hare JM
Am J Physiol Heart Circ Physiol; 2023 Jun; 324(6):H739-H750. PubMed ID: 36897749
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction.
Rieger AC; Bagno LL; Salerno A; Florea V; Rodriguez J; Rosado M; Turner D; Dulce RA; Takeuchi LM; Kanashiro-Takeuchi RM; Buchwald P; Wanschel ACBA; Balkan W; Schulman IH; Schally AV; Hare JM
Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468654
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
Alex L; Russo I; Holoborodko V; Frangogiannis NG
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a robust mouse model of heart failure with preserved ejection fraction.
Matsiukevich D; Kovacs A; Li T; Kokkonen-Simon K; Matkovich SJ; Oladipupo SS; Ornitz DM
Am J Physiol Heart Circ Physiol; 2023 Aug; 325(2):H203-H231. PubMed ID: 37204871
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure.
Gesmundo I; Miragoli M; Carullo P; Trovato L; Larcher V; Di Pasquale E; Brancaccio M; Mazzola M; Villanova T; Sorge M; Taliano M; Gallo MP; Alloatti G; Penna C; Hare JM; Ghigo E; Schally AV; Condorelli G; Granata R
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):12033-12038. PubMed ID: 29078377
[TBL] [Abstract][Full Text] [Related]
7. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
Mátyás C; Németh BT; Oláh A; Török M; Ruppert M; Kellermayer D; Barta BA; Szabó G; Kökény G; Horváth EM; Bódi B; Papp Z; Merkely B; Radovits T
Eur J Heart Fail; 2017 Mar; 19(3):326-336. PubMed ID: 27995696
[TBL] [Abstract][Full Text] [Related]
8. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
Paulus WJ; Tschöpe C
J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
[TBL] [Abstract][Full Text] [Related]
9. Cardiomyocyte Functional Etiology in Heart Failure With Preserved Ejection Fraction Is Distinctive-A New Preclinical Model.
Curl CL; Danes VR; Bell JR; Raaijmakers AJA; Ip WTK; Chandramouli C; Harding TW; Porrello ER; Erickson JR; Charchar FJ; Kompa AR; Edgley AJ; Crossman DJ; Soeller C; Mellor KM; Kalman JM; Harrap SB; Delbridge LMD
J Am Heart Assoc; 2018 Jun; 7(11):. PubMed ID: 29858360
[TBL] [Abstract][Full Text] [Related]
10. Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling.
Wu H; Tang LX; Wang XM; Li LP; Chen XK; He YJ; Yang DZ; Shi Y; Shou JL; Zhang ZS; Wang L; Lu BJ; An SM; Zeng CY; Wang WE
Acta Pharmacol Sin; 2023 Jun; 44(6):1149-1160. PubMed ID: 36473990
[TBL] [Abstract][Full Text] [Related]
11. Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction.
Monma Y; Shindo T; Eguchi K; Kurosawa R; Kagaya Y; Ikumi Y; Ichijo S; Nakata T; Miyata S; Matsumoto A; Sato H; Miura M; Kanai H; Shimokawa H
Cardiovasc Res; 2021 Apr; 117(5):1325-1338. PubMed ID: 32683442
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction.
Ainscough JF; Drinkhill MJ; Sedo A; Turner NA; Brooke DA; Balmforth AJ; Ball SG
Cardiovasc Res; 2009 Feb; 81(3):592-600. PubMed ID: 18703536
[TBL] [Abstract][Full Text] [Related]
13. Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype.
Li Y; Kubo H; Yu D; Yang Y; Johnson JP; Eaton DM; Berretta RM; Foster M; McKinsey TA; Yu J; Elrod JW; Chen X; Houser SR
Am J Physiol Heart Circ Physiol; 2023 Apr; 324(4):H443-H460. PubMed ID: 36763506
[TBL] [Abstract][Full Text] [Related]
14. Right-ventricular dysfunction in HFpEF is linked to altered cardiomyocyte Ca
Hegemann N; Primessnig U; Bode D; Wakula P; Beindorff N; Klopfleisch R; Michalick L; Grune J; Hohendanner F; Messroghli D; Pieske B; Kuebler WM; Heinzel FR
ESC Heart Fail; 2021 Aug; 8(4):3130-3144. PubMed ID: 34002482
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.
Chang D; Xu TT; Zhang SJ; Cai Y; Min SD; Zhao Z; Lu CQ; Wang YC; Ju S
Exp Biol Med (Maywood); 2021 Dec; 246(23):2511-2521. PubMed ID: 34342551
[TBL] [Abstract][Full Text] [Related]
16. Cellular mechanisms of metabolic syndrome-related atrial decompensation in a rat model of HFpEF.
Hohendanner F; Bode D; Primessnig U; Guthof T; Doerr R; Jeuthe S; Reimers S; Zhang K; Bach D; Wakula P; Pieske BM; Heinzel FR
J Mol Cell Cardiol; 2018 Feb; 115():10-19. PubMed ID: 29289652
[TBL] [Abstract][Full Text] [Related]
17. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction.
Fan D; Takawale A; Basu R; Patel V; Lee J; Kandalam V; Wang X; Oudit GY; Kassiri Z
Cardiovasc Res; 2014 Jul; 103(2):268-80. PubMed ID: 24692173
[TBL] [Abstract][Full Text] [Related]
18. A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II.
Regan JA; Mauro AG; Carbone S; Marchetti C; Gill R; Mezzaroma E; Valle Raleigh J; Salloum FN; Van Tassell BW; Abbate A; Toldo S
Am J Physiol Heart Circ Physiol; 2015 Sep; 309(5):H771-8. PubMed ID: 26188021
[TBL] [Abstract][Full Text] [Related]
19. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction.
Hamdani N; Bishu KG; von Frieling-Salewsky M; Redfield MM; Linke WA
Cardiovasc Res; 2013 Mar; 97(3):464-71. PubMed ID: 23213108
[TBL] [Abstract][Full Text] [Related]
20. Early calcium handling imbalance in pressure overload-induced heart failure with nearly normal left ventricular ejection fraction.
Rouhana S; Farah C; Roy J; Finan A; Rodrigues de Araujo G; Bideaux P; Scheuermann V; Saliba Y; Reboul C; Cazorla O; Aimond F; Richard S; Thireau J; Fares N
Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):230-242. PubMed ID: 30463691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
